Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK

Shobhit Baijal, Philip Crosbie, Jackie Fenemore, Ketul Desai

Research output: Contribution to journalArticlepeer-review

Abstract

This survey aims to understand the current UK practice for non-small cell lung carcinoma (NSCLC) and identify barriers that may impact patient treatment and outcomes. In March–June 2021, 57 interviews were conducted with healthcare professionals involved in the secondary care management of patients with NSCLC. Most respondents performed genetic testing at onsite and non-genomic laboratory hub (GLH) offsite locations. The most common genetic tests were EGFR T790M variant (100%), EGFR exon 18-21 covered (95%) and BRAF (93%). No targeted therapy (TT) available (69%), lack of access to a TT (54%) or excessive molecular testing turnaround times (39%) were the most common reasons for using an immuno-oncology therapy over a TT in the first-line setting. The survey highlights variation in mutation testing practices across the UK, which may impact treatment decisions and contribute to health outcome inequality.

Original languageEnglish
Pages (from-to)E699-E702
JournalOncologist
Volume28
Issue number8
Early online date13 Jun 2023
DOIs
Publication statusPublished - 1 Aug 2023

Keywords

  • management
  • non-small cell lung carcinoma
  • oncogenic genetic testing
  • real world practice
  • treatment

Fingerprint

Dive into the research topics of 'Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK'. Together they form a unique fingerprint.

Cite this